Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1983 Aug;24(2):176–180. doi: 10.1128/aac.24.2.176

Use of ceftazidime in the therapy of serious infections, including those due to multiresistant organisms.

N Clumeck, Y Van Laethem, B Gordts, N Jaspar, J P Butzler
PMCID: PMC185133  PMID: 6357068

Abstract

Ceftazidime was administered intravenously or intramuscularly or both in doses of 1 to 6 g per day to 33 patients with serious gram-negative bacillary infections (12 pulmonary, 10 urinary tract, 4 soft tissue, 4 intraabdominal, and 3 miscellaneous infections). Twenty-one patients were septicemic. We identified 20 isolates of members of the family Enterobacteriaceae and 13 isolates of Pseudomonas aeruginosa. Seventeen patients had failed to respond to previous antimicrobial therapy. A total of 23 patients were clinically cured, 7 patients improved, and 3 patients failed to respond to therapy. The selection or emergence of resistant organisms during treatment (mostly Candida spp., Staphylococcus aureus, and enterococci) was noted in 11 patients. Toxicity was minimal (reversible mild liver function abnormalities and eosinophilia). The results of this study suggest that ceftazidime is an effective and well-tolerated new cephalosporin for the therapy of serious infections due to susceptible gram-negative organisms.

Full text

PDF
177

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Clumeck N., van Laethem Y., Vanhoof R., George C., Rapin M., Butzler J. P. Cefotaxime therapy of serious infections with multiresistant gram-negative bacilli. Scand J Infect Dis. 1982;14(1):57–60. doi: 10.3109/inf.1982.14.issue-1.11. [DOI] [PubMed] [Google Scholar]
  2. Gordts B., Dab I., Butzler J. P. Ceftazidime in cystic fibrosis. Lancet. 1982 Jun 12;1(8285):1355–1355. doi: 10.1016/s0140-6736(82)92417-5. [DOI] [PubMed] [Google Scholar]
  3. Gozzard D. I., Geddes A. M., Farrell I. D., Eykyn S. J., Phillips I., Wise R., Brown R. M. Ceftazidime--a new extended-spectrum cephalosporin. Lancet. 1982 May 22;1(8282):1152–1156. doi: 10.1016/s0140-6736(82)92228-0. [DOI] [PubMed] [Google Scholar]
  4. Greenwood D., Eley A. Comparative antipseudomonal activity of some newer beta-lactam agents. Antimicrob Agents Chemother. 1982 Feb;21(2):204–209. doi: 10.1128/aac.21.2.204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Lüthy R., Blaser J., Bonetti A., Simmen H., Wise R., Siegenthaler W. Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. Antimicrob Agents Chemother. 1981 Nov;20(5):567–575. doi: 10.1128/aac.20.5.567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Mathisen G. E., Meyer R. D., Thompson J. M., Finegold S. M. Clinical evaluation of moxalactam. Antimicrob Agents Chemother. 1982 May;21(5):780–786. doi: 10.1128/aac.21.5.780. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Neu H. C. The new beta-lactamase-stable cephalosporins. Ann Intern Med. 1982 Sep;97(3):408–419. doi: 10.7326/0003-4819-97-3-408. [DOI] [PubMed] [Google Scholar]
  8. O'Callaghan C. H., Acred P., Harper P. B., Ryan D. M., Kirby S. M., Harding S. M. GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity. Antimicrob Agents Chemother. 1980 May;17(5):876–883. doi: 10.1128/aac.17.5.876. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Schleupner C. J., Engle J. C. Clinical evaluation of cefotaxime for therapy of lower respiratory tract infections. Antimicrob Agents Chemother. 1982 Feb;21(2):327–333. doi: 10.1128/aac.21.2.327. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Venezio F. R., Westenfelder G. O., Cook F. V., Williams J. E., Carruthers M., Reisberg B. E., Emmerman J., Phair J. P. Clinical evaluation of moxalactam therapy. J Antimicrob Chemother. 1982 Nov;10(5):435–443. doi: 10.1093/jac/10.5.435. [DOI] [PubMed] [Google Scholar]
  11. Verbist L., Verhaegen J. GR-20263: a new aminothiazolyl cephalosporin with high activity against Pseudomonas and Enterobacteriaceae. Antimicrob Agents Chemother. 1980 May;17(5):807–812. doi: 10.1128/aac.17.5.807. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Winston D. J., Busuttil R. W., Kurtz T. O., Young L. S. Moxalactam therapy for bacterial infections. Arch Intern Med. 1981 Nov;141(12):1607–1612. [PubMed] [Google Scholar]
  13. Wise R., Andrews J. M., Bedford K. A. Comparison of in vitro activity of GR 20263, a novel cephalosporin derivative, with activities of other beta-lactam compounds. Antimicrob Agents Chemother. 1980 May;17(5):884–889. doi: 10.1128/aac.17.5.884. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Yu V. L. Enterococcal superinfection and colonization after therapy with moxalactam, a new broad-spectrum antibiotic. Ann Intern Med. 1981 Jun;94(6):784–785. doi: 10.7326/0003-4819-94-6-784. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES